Facet seeks better offer after Biogen Idec's bid falls through
This article was originally published in Scrip
Facet Biotech is looking for companies to acquire it on better terms than the $17.50 per share offer by Biogen Idec that fell through this week. President and CEO Faheem Hasnain added that Facet continued "to offer Biogen Idec the opportunity to engage in due diligence discussions to determine whether [the latter] would make a materially increased offer".
You may also be interested in...
Fundraising in the life sciences sector has been booming even as firms in many other industries are struggling to stay in business. Goodwin’s David Mardle is upbeat about the sector’s ongoing prospects – although M&A deals are currently proving tricky to complete.
See how much the CEOs and R&D heads of the world’s biggest pharma companies get paid, and how those companies are performing.
Merck & Co is gradually catching up with Roche in PD-1/L1 first-line triple-negative breast cancer treatment, but its presentation at ASCO on Keynote-355 includes mixed PFS results. Overall survival data will be key to Keytruda’s competitiveness.